Trial of Pegcetacoplan in C3 Glomerulopathy and Immune-Complex MPGN

202515 citationsJournal Article

Authors

Fádi Fakhouri · University of Lausanne

Andrew S. Bomback · Columbia University Irving Medical Center

Gema Ariceta · Vall d'Hebron Hospital Universitari

Yahsou Delmas · Bordeaux Population Health

Bradley P. Dixon · University of Colorado Denver

Daniel P. Gale · University College London

Larry A. Greenbaum

Abstract

Pegcetacoplan resulted in a significantly greater reduction in proteinuria than placebo among patients with C3 glomerulopathy or primary immune-complex MPGN. (Funded by Apellis Pharmaceuticals and Sobi [Swedish Orphan Biovitrum]; VALIANT ClinicalTrials.gov number, NCT05067127.).

Topics & Keywords

Complement system in diseases Peripheral Neuropathies and Disorders Coagulation, Bradykinin, Polyphosphates, and Angioedema

Publication Details

Published in: New England Journal of Medicine

Volume 393, Issue 22, pp. 2210-2220

DOI: 10.1056/nejmoa2501510

Field-Weighted Citation Impact: 11.68

Command Palette

Trial of Pegcetacoplan in C3 Glomerulopathy and Immune-Complex MPGN

Authors

Abstract

Topics & Keywords

Publication Details